EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025
EyePoint Pharmaceuticals (NASDAQ: EYPT), a pharmaceutical company focused on developing innovative therapeutics for serious retinal diseases, has scheduled its second quarter 2025 financial results conference call and webcast for August 6, 2025, at 8:30 a.m. ET.
During the call, management will discuss Q2 2025 financial performance and provide updates on recent corporate developments. Investors can access the live conference call through registration and join the webcast through the company's investor relations website.
EyePoint Pharmaceuticals (NASDAQ: EYPT), un'azienda farmaceutica specializzata nello sviluppo di terapie innovative per gravi malattie retiniche, ha programmato la conferenza telefonica e la trasmissione web dei risultati finanziari del secondo trimestre 2025 per il 6 agosto 2025 alle 8:30 ET.
Durante la chiamata, il management discuterà le performance finanziarie del secondo trimestre 2025 e fornirà aggiornamenti sugli sviluppi aziendali recenti. Gli investitori potranno accedere alla conferenza telefonica in diretta registrandosi e partecipare alla trasmissione web tramite il sito web delle relazioni con gli investitori della società.
EyePoint Pharmaceuticals (NASDAQ: EYPT), una compañía farmacéutica centrada en desarrollar terapias innovadoras para enfermedades retinianas graves, ha programado su llamada conferencia y webcast de los resultados financieros del segundo trimestre de 2025 para el 6 de agosto de 2025 a las 8:30 a.m. ET.
Durante la llamada, la dirección discutirá el desempeño financiero del segundo trimestre de 2025 y proporcionará actualizaciones sobre los recientes desarrollos corporativos. Los inversores pueden acceder a la llamada en vivo registrándose y unirse al webcast a través del sitio web de relaciones con inversores de la compañía.
EyePoint Pharmaceuticals (NASDAQ: EYPT)는 심각한 망막 질환을 위한 혁신적인 치료제를 개발하는 제약 회사로, 2025년 2분기 재무 실적에 관한 컨퍼런스 콜 및 웹캐스트를 2025년 8월 6일 오전 8시 30분 ET에 예정했습니다.
콜 동안 경영진은 2025년 2분기 재무 성과를 논의하고 최근 기업 동향에 대한 업데이트를 제공할 예정입니다. 투자자들은 등록을 통해 라이브 컨퍼런스 콜에 참여할 수 있으며, 회사 투자자 관계 웹사이트를 통해 웹캐스트에 접속할 수 있습니다.
EyePoint Pharmaceuticals (NASDAQ : EYPT), une société pharmaceutique spécialisée dans le développement de traitements innovants pour les maladies rétiniennes graves, a programmé sa conférence téléphonique et son webcast des résultats financiers du deuxième trimestre 2025 pour le 6 août 2025 à 8h30 ET.
Lors de cet appel, la direction discutera des performances financières du deuxième trimestre 2025 et fournira des mises à jour sur les récents développements de l'entreprise. Les investisseurs peuvent accéder à la conférence téléphonique en direct en s'inscrivant et rejoindre le webcast via le site web des relations investisseurs de la société.
EyePoint Pharmaceuticals (NASDAQ: EYPT), ein Pharmaunternehmen, das sich auf die Entwicklung innovativer Therapien für schwere Netzhauterkrankungen spezialisiert hat, hat seine Telefonkonferenz und Webcast zu den Finanzergebnissen des zweiten Quartals 2025 für den 6. August 2025 um 8:30 Uhr ET angesetzt.
Während des Anrufs wird das Management die finanzielle Leistung des zweiten Quartals 2025 besprechen und Updates zu aktuellen Unternehmensentwicklungen geben. Investoren können die Live-Telefonkonferenz durch Registrierung verfolgen und über die Investor-Relations-Website des Unternehmens am Webcast teilnehmen.
- None.
- None.
WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and highlight recent corporate developments.
To access the live conference call, please register using the audio conference link: https://register-conf.media-server.com/register/BI2f02d8b4966b40da83f2ef4135b2ba78. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call.
About EyePoint
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data to date, DURAVYU is currently being evaluated in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) with topline data anticipated in 2026. DURAVYU also completed a positive Phase 2 clinical trial in diabetic macular edema (DME) with Phase 3 pivotal planning underway. Despite current therapies, patients with wet AMD and DME still tend to lose vision in the long term and wet AMD is the leading cause of vision loss among people 50 years of age and older in the United States.
The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.
EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product candidate; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
FAQ
When will EyePoint Pharmaceuticals (EYPT) report Q2 2025 earnings?
How can investors access EYPT's Q2 2025 earnings call?
What will be discussed in EyePoint's Q2 2025 earnings call?
Where can I find the replay of EYPT's Q2 2025 earnings webcast?
